These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 24750493)
1. The AMPA receptor antagonist perampanel is a new hope in the treatment for epilepsy. El Desoky ES Fundam Clin Pharmacol; 2014 Oct; 28(5):473-80. PubMed ID: 24750493 [TBL] [Abstract][Full Text] [Related]
3. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307. Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Squillacote D; Yang H; Gee M; Zhu J; Laurenza A Epilepsia; 2013 Jan; 54(1):126-34. PubMed ID: 22905878 [TBL] [Abstract][Full Text] [Related]
4. AMPA receptor inhibitors for the treatment of epilepsy: the role of perampanel. Zaccara G; Giovannelli F; Cincotta M; Iudice A Expert Rev Neurother; 2013 Jun; 13(6):647-55. PubMed ID: 23739002 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Steinhoff BJ; Ben-Menachem E; Ryvlin P; Shorvon S; Kramer L; Satlin A; Squillacote D; Yang H; Zhu J; Laurenza A Epilepsia; 2013 Aug; 54(8):1481-9. PubMed ID: 23663001 [TBL] [Abstract][Full Text] [Related]
6. The discovery and development of perampanel for the treatment of epilepsy. Hanada T Expert Opin Drug Discov; 2014 Apr; 9(4):449-58. PubMed ID: 24559052 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. French JA; Krauss GL; Steinhoff BJ; Squillacote D; Yang H; Kumar D; Laurenza A Epilepsia; 2013 Jan; 54(1):117-25. PubMed ID: 22905857 [TBL] [Abstract][Full Text] [Related]
8. Perampanel, an antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent models. Zwart R; Sher E; Ping X; Jin X; Sims JR; Chappell AS; Gleason SD; Hahn PJ; Gardinier K; Gernert DL; Hobbs J; Smith JL; Valli SN; Witkin JM J Pharmacol Exp Ther; 2014 Oct; 351(1):124-33. PubMed ID: 25027316 [TBL] [Abstract][Full Text] [Related]
9. Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures. Rektor I Expert Opin Pharmacother; 2013 Feb; 14(2):225-35. PubMed ID: 23259931 [TBL] [Abstract][Full Text] [Related]
10. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures. Gidal BE; Ferry J; Majid O; Hussein Z Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853 [TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of perampanel: a review of clinical trial data. Serratosa JM; Villanueva V; Kerling F; Kasper BS Acta Neurol Scand Suppl; 2013; (197):30-5. PubMed ID: 23480154 [TBL] [Abstract][Full Text] [Related]
12. Perampanel: Does it have broad-spectrum potential? Potschka H; Trinka E Epilepsia; 2019 Mar; 60 Suppl 1():22-36. PubMed ID: 29953584 [TBL] [Abstract][Full Text] [Related]
13. The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. Patsalos PN Epilepsia; 2015 Jan; 56(1):12-27. PubMed ID: 25495693 [TBL] [Abstract][Full Text] [Related]
14. Perampanel: A Review in Drug-Resistant Epilepsy. Frampton JE Drugs; 2015 Sep; 75(14):1657-68. PubMed ID: 26370209 [TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study. Singh K; Shah YD; Luciano D; Friedman D; Devinsky O; Kothare SV Epilepsy Behav; 2016 Aug; 61():41-45. PubMed ID: 27300147 [TBL] [Abstract][Full Text] [Related]
16. AMPA receptors and perampanel behind selected epilepsies: current evidence and future perspectives. Di Bonaventura C; Labate A; Maschio M; Meletti S; Russo E Expert Opin Pharmacother; 2017 Nov; 18(16):1751-1764. PubMed ID: 29023170 [TBL] [Abstract][Full Text] [Related]
17. Introduction: Perampanel--new mode of action and new option for patients with epilepsy. Steinhoff BJ Epilepsia; 2014 Jan; 55 Suppl 1():1-2. PubMed ID: 24400689 [TBL] [Abstract][Full Text] [Related]
18. Perampanel: as adjunctive therapy in patients with partial-onset seizures. Plosker GL CNS Drugs; 2012 Dec; 26(12):1085-96. PubMed ID: 23179642 [TBL] [Abstract][Full Text] [Related]
19. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Krauss GL; Serratosa JM; Villanueva V; Endziniene M; Hong Z; French J; Yang H; Squillacote D; Edwards HB; Zhu J; Laurenza A Neurology; 2012 May; 78(18):1408-15. PubMed ID: 22517103 [TBL] [Abstract][Full Text] [Related]
20. Development of perampanel in epilepsy. Satlin A; Kramer LD; Laurenza A Acta Neurol Scand Suppl; 2013; (197):3-8. PubMed ID: 23480150 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]